Clinical outcomes with first-line chemotherapy versus endocrine therapy for adjuvant endocrine therapy-resistant metastatic breast cancer

被引:0
作者
Shao, Bin [1 ]
Yang, Yanlian [2 ]
Qu, Jinrong [3 ]
Li, Huiping [1 ]
Song, Guohong [1 ]
Di, Lijun [1 ]
Jiang, Hanfang [1 ]
Yan, Ying [1 ]
Wang, Huan [1 ]
Liu, Xiaoran [1 ]
Wang, Jing [1 ]
Kong, Weiyao [1 ]
机构
[1] Peking Univ, Canc Hosp & Inst, Minist Educ, Dept Med Oncol,Key Lab Carcinogenesis & Translat, Beijing 100142, Peoples R China
[2] CAS Ctr Excellence Nanosci, Natl Ctr Nanosci & Technol, CAS Key Lab Standardizat & Measurement Nanotechno, Beijing 100190, Peoples R China
[3] Shijiazhuang Third Hosp, Dept Oncol & Hematol, Shijiazhuang 050011, Hebei, Peoples R China
基金
北京市自然科学基金;
关键词
Endocrine resistance; ER+/HER2-; metastatic breast cancer (MBC); endocrine therapy (ET); chemotherapy (CT); PHASE-III; AROMATASE INHIBITORS; MAINTENANCE THERAPY; RANDOMIZED-TRIAL; MULTICENTER; CONSENSUS; BEVACIZUMAB; ANASTROZOLE; DOXORUBICIN; PACLITAXEL;
D O I
10.21037/tcr.2018.05.43
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Endocrine therapy resistance (ETR) is a great obstacle in the treatment of estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Patients with ETR have significantly decreased clinical benefit from endocrine therapy (ET). Therefore, it is quite important to find the clinicopathological factors that affect the outcome of patients with ETR in clinical practice. Method: We screened 405 consecutive ER+/HER2- metastatic breast cancer (MBC) patients who were treated from 2013-2015 in our hospital. Patients with ETR (defined as relapse during adjuvant ET or within 12 months after completing adjuvant ET) were selected to explore the clinicopathological factors affecting the objective response rate (ORR) and progression-free survival (PFS). Results: We included 135 patients in the study. Chemotherapy (CT) was administered to 96 patients and ET to 39 patients as first-line treatment. Patients with liver or visceral metastasis received CT significantly more frequently than ET (P=0.001, 0.001). There was no significant difference in median PFS between the two groups (ET: 11.8 months, CT: 12.0 months, P=0.667, HR =1.029). However, patients with more than two metastatic sites had a shorter PFS than patients with less than or equal to two metastatic sites (7.5 vs. 14.5 months, P=0.031, HR =1.714). When patients on CT were further stratified, those who received ET as maintenance therapy had a longer PFS (14.3 months) compared with those that did not (7.5 months) (P=0.003). Conclusions: ET and CT were both appropriate treatments for patients with ETR. Maintenance ET was a good choice for ER+/HER2- patients.
引用
收藏
页码:676 / 685
页数:10
相关论文
共 50 条
[21]   First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients [J].
Liang, Xu ;
Yan, Ying ;
Wang, Lina ;
Song, Guohong ;
Di, Lijun ;
Jiang, Hanfang ;
Wang, Chaoying ;
Li, Huiping .
ONCOLOGY LETTERS, 2015, 9 (02) :987-993
[22]   Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer [J].
Yuan, Yang ;
Zhang, Shaohua ;
Wang, Tao ;
Bian, Li ;
Yan, Min ;
Yin, Yongmei ;
Song, Yuhua ;
Wen, Yi ;
Li, Jianbin ;
Jiang, Zefei .
CHINESE MEDICAL JOURNAL, 2023, 136 (12) :1459-1467
[23]   Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer [J].
Yuan Yang ;
Zhang Shaohua ;
Wang Tao ;
Bian Li ;
Yan Min ;
Yin Yongmei ;
Song Yuhua ;
Wen Yi ;
Li Jianbin ;
Jiang Zefei .
中华医学杂志英文版, 2023, 136 (12)
[24]   Endocrine Therapy for Advanced/Metastatic Breast Cancer [J].
Schiavon, Gaia ;
Smith, Ian E. .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 27 (04) :715-+
[25]   Updates in endocrine therapy for metastatic breast cancer [J].
Manohar, Poorni M. ;
Davidson, Nancy E. .
CANCER BIOLOGY & MEDICINE, 2022, 19 (02) :202-212
[26]   Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer [J].
Li, Li ;
Chang, Bingmei ;
Jiang, Xiaoyue ;
Fan, Xueke ;
Li, Yingrui ;
Li, Teng ;
Wu, Shanshan ;
Zhang, Jun ;
Kariminia, Seyed ;
Li, Qin .
BMC CANCER, 2018, 18
[27]   Neoadjuvant Endocrine Therapy for Breast Cancer [J].
Chawla, Jane S. ;
Ma, Cynthia X. ;
Ellis, Matthew J. .
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 19 (03) :627-+
[28]   Adherence to Endocrine Therapy in Breast Cancer Adjuvant and Prevention Settings [J].
Chlebowski, Rowan T. ;
Kim, Jisang ;
Haque, Reina .
CANCER PREVENTION RESEARCH, 2014, 7 (04) :378-387
[29]   Adjuvant endocrine therapy for perimenopausal women with early breast cancer [J].
Ortmann, Olaf ;
Cufer, Tanja ;
Dixon, J. Michael ;
Maass, Nicolai ;
Marchetti, Paolo ;
Pagani, Olivia ;
Pronzato, Paolo ;
Semiglazov, Vladimir ;
Spano, Jean-Philippe ;
Vrdoljak, Eduard ;
Wildiers, Hans .
BREAST, 2009, 18 (01) :2-7
[30]   Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer [J].
Kuba, Sayaka ;
Ishida, Mayumi ;
Nakamura, Yoshiaki ;
Taguchi, Kenichi ;
Ohno, Shinji .
BREAST CANCER, 2016, 23 (01) :128-133